Discover trends, market shifts, and competitive outlooks for the methylmalonic acidemia (mma) industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

How Has The Methylmalonic Acidemia (MMA) Market Size Shifted, And What Is the Outlook Through 2034?

In recent times, the market size for methylmalonic acidemia (MMA) has experienced robust growth. It is expected to increase from $9.39 billion in 2024 to $9.97 billion in 2025, with a compound annual growth rate (CAGR) of 6.2%. The notable growth during the historic period can be linked to factors such as increased rates of metabolic disorders and vitamin deficiencies, amplified spending in healthcare, a heightened awareness of health, a climbing prevalence of genetic disorders, and increasing demand across numerous end-user industries.

The market size for methylmalonic acidemia (MMA) is predicted to experience significant expansion in the upcoming years, with projections expecting it to reach $12.50 billion by 2029, at a compound annual growth rate (CAGR) of 5.8%. The predicted growth in the forecast period can be credited to factors such as an upswing in newborn screening programs, heightened awareness amongst medical professionals, a surge in gene therapy developments, increased funding in research for rare diseases and growing accessibility of specialized treatments. Major trends predicted for the period include progress in gene editing technologies, cutting-edge diagnostic methods for early detection, advances in enzyme replacement therapies along with the adoption of precision medicine strategies, and an increase in newborn genetic screening programs.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22057&type=smp

What are the Fundamental Drivers and Innovations Shaping the Methylmalonic Acidemia (MMA) Market?

The methylmalonic acidemia (MMA) market is expected to grow due to the rising prevalence of metabolic disorders and vitamin deficiencies. Metabolic disorders refer to a set of conditions where the body fails to process particular nutrients, generate energy, or control chemical reactions within cells. Vitamin deficiencies inch up when the body doesn’t have enough specific vitamins to perform ordinarily. This increase in metabolic disorders and vitamin deficiencies can be attributed to unhealthy eating habits, inactive lifestyles, and heightened stress levels. Contemporary diets are typically filled with processed foods, sugars, and unhealthy fats, while lacking in crucial nutrients, resulting in deficiencies of vitamins and minerals. Increasingly, with the rise in metabolic disorders and vitamin deficiencies — particularly vitamin B12 — the metabolism of methylmalonyl-CoA is adversely affected leading to the accumulation of methylmalonic acid, worsening methylmalonic acidemia (MMA). For example, in November 2024 according to the National Institutes of Health, a US-based government body, the occurrence of vitamin B12 deficiency went up from 4.6% to 5.2%, denoting an additional 507 cases between the third and fourth quarters of 2023. Consequently, the rise in metabolic disorders and vitamin deficiencies fuels the growth of the methylmalonic acidemia (MMA) market.

How Is the Methylmalonic Acidemia (MMA) Market Segmented?

The methylmalonic acidemia (MMA) market covered in this report is segmented –

1) By Indication: Acidosis, Ketosis, Hyperammonemia, Hypoglycaemia, Hyperglycaemia, Neutropenia, Other Indications

2) By Disorder Type: Homocystinuria, Isolated Methylmalonic Acidurias, Combined methylmalonic Aciduria

3) By Distribution Channel: Hospitals, Pharmacies, Clinics, Other Distribution Channels

Subsegments:

1) By Acidosis: Metabolic Acidosis, Lactic Acidosis

2) By Ketosis: Starvation-Induced Ketosis, Diabetic Ketoacidosis

3) By Hyperammonemia: Acute Hyperammonemia, Chronic Hyperammonemia

4) By Hypoglycemia: Fasting Hypoglycemia, Reactive Hypoglycemi

5) By Hyperglycemia: Transient Hyperglycemia, Persistent Hyperglycemia

6) By Neutropenia: Severe Neutropenia, Cyclic Neutropenia

7) By Other Indications: Failure to Thrive, Developmental Delays, Neurological Symptoms, Renal Dysfunction

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=22057&type=smp

Which Regions Are Driving the Next Phase of the Methylmalonic Acidemia (MMA) Market Growth?

North America was the largest region in the methylmalonic acidemia (MMA) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the methylmalonic acidemia (MMA) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Trends Are Shaping the Future of the Methylmalonic Acidemia (MMA) Market?

Key players in the methylmalonic acidemia (MMA) market are prioritizing the creation of new solutions, including mRNA-based therapies, with the goal of enhancing treatment results. These therapies aim to address the root genetic factors causing MMA and promote enzymatic function to curb toxic metabolite buildup in those affected. mRNA-based therapies involve the use of mRNA to instruct cells on generating certain proteins that could avert or manage diseases such as genetic disorders or infections. Take for example, Moderna, Inc., a pharmaceutical and biotechnology firm based in the US. In June 2024, the company received approval from the U.S. Food and Drug Administration (FDA) to include mRNA-3705 in the START pilot program – a major leap in improving treatments for rare diseases. mRNA-3705 is an experimental treatment for MMA caused by a MUT deficiency, engineered to reintroduce the absent enzyme via mRNA technology. The treatment harnesses the proprietary lipid nanoparticle (LNP) mechanism of Moderna, also operational in the mRNA-3927 initiative for propionic acidemia. The FDA has accorded mRNA-3705 with orphan drug, fast track, and rare pediatric disease designations, therefore expediting its evolution and clinical progression.

View the full report here:

https://www.thebusinessresearchcompany.com/report/methylmalonic-acidemia-mma-global-market-report

How Is the Methylmalonic Acidemia (MMA) Market Defined and What Are Its Core Parameters?

Methylmalonic acidemia (MMA) is a rare, inherited metabolic disorder in which the body is unable to properly break down specific proteins and fats due to a deficiency in the enzyme methylmalonyl-CoA mutase or a related coenzyme, vitamin B12. The symptoms of MMA can vary in severity but often include vomiting, lethargy, poor feeding, developmental delay, seizures, and failure to thrive.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22057

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model